$NRXP
NRX Pharmaceuticals, Inc.

2021 Q4 Form 10-Q Financial Statement

#000155837021015962 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $46.56M $13.82M $169.0K
YoY Change 10534.92% 8077.98% -6.09%
% of Gross Profit
Research & Development $6.413M $6.276M $4.332M
YoY Change 44.88%
% of Gross Profit
Depreciation & Amortization $390.00 $640.00
YoY Change
% of Gross Profit
Operating Expenses $52.98M $20.10M $5.149M
YoY Change 11999.76% 290.34% 2760.67%
Operating Profit -$20.10M -$5.149M
YoY Change 290.34%
Interest Expense $481.3K $5.368K $12.51K
YoY Change -173.47% -57.1% -95.19%
% of Operating Profit
Other Income/Expense, Net $21.70M -$673.9K -$12.51K
YoY Change 5285.98%
Pretax Income -$30.79M -$20.77M -$5.162M
YoY Change 2717.79% 302.45% -7473.87%
Income Tax $0.00 $0.00 -$42.69K
% Of Pretax Income
Net Earnings -$30.79M -$20.77M -$5.162M
YoY Change 2731.68% 302.45% -8702.85%
Net Earnings / Revenue
Basic Earnings Per Share -$0.40 -$0.15
Diluted Earnings Per Share -$532.8K -$0.40 -$0.15
COMMON SHARES
Basic Shares Outstanding 58.81M 51.74M 34.14M
Diluted Shares Outstanding 51.05M 34.14M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.61M $38.88M $40.02K
YoY Change 5873304.26% 97060.34% -78.94%
Cash & Equivalents $27.61M $38.88M
Short-Term Investments
Other Short-Term Assets $5.109M $6.351M $57.09K
YoY Change 19550.0% 11024.35% 470.9%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $32.71M $45.23M $97.10K
YoY Change 1016.52% 46485.44% -53.76%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.935M
YoY Change -85.69%
Other Assets $15.00K $15.92K
YoY Change 36.36%
Total Long-Term Assets $15.00K $15.92K $5.935M
YoY Change 36.36% -99.73% -85.69%
TOTAL ASSETS
Total Short-Term Assets $32.71M $45.23M $97.10K
Total Long-Term Assets $15.00K $15.92K $5.935M
Total Assets $32.73M $45.25M $6.032M
YoY Change 1012.85% 650.2% -85.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.687M $5.559M $379.2K
YoY Change 16.94% 1366.09% -29.78%
Accrued Expenses $2.375M $1.996M
YoY Change 37.36%
Deferred Revenue $292.0K $775.3K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $518.0K $515.1K
YoY Change
Total Short-Term Liabilities $11.92M $36.28M $379.2K
YoY Change -74.17% 9468.3% -40.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $2.451M
YoY Change -100.0% -100.0% 36.95%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $2.451M
YoY Change -100.0% -100.0% 36.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.92M $36.28M $379.2K
Total Long-Term Liabilities $0.00 $0.00 $2.451M
Total Liabilities $11.92M $36.28M $2.831M
YoY Change -74.48% 1181.83% 16.48%
SHAREHOLDERS EQUITY
Retained Earnings -$183.2M -$152.4M
YoY Change 103.2%
Common Stock $59.00K $54.81K
YoY Change 37.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.81M $8.967M -$2.829M
YoY Change
Total Liabilities & Shareholders Equity $32.73M $45.25M $6.032M
YoY Change 1012.85% 650.2% -85.53%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$30.79M -$20.77M -$5.162M
YoY Change 2731.68% 302.45% -8702.85%
Depreciation, Depletion And Amortization $390.00 $640.00
YoY Change
Cash From Operating Activities -$11.28M -$12.01M -$64.67K
YoY Change 4867.81% 18478.89% 29.34%
INVESTING ACTIVITIES
Capital Expenditures -$390.00 -$3.830K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $306.1K
YoY Change -96.57%
Cash From Investing Activities -$390.00 -$3.830K $306.1K
YoY Change -98.82% -101.25% -96.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.230K 37.52M -201.5K
YoY Change -99.44% -18722.08% -97.68%
NET CHANGE
Cash From Operating Activities -11.28M -12.01M -64.67K
Cash From Investing Activities -390.0 -3.830K 306.1K
Cash From Financing Activities 1.230K 37.52M -201.5K
Net Change In Cash -11.28M 25.50M 40.01K
YoY Change 28411.27% 63627.17% -78.94%
FREE CASH FLOW
Cash From Operating Activities -$11.28M -$12.01M -$64.67K
Capital Expenditures -$390.00 -$3.830K
Free Cash Flow -$11.28M -$12.01M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Depreciation
Depreciation
1605
us-gaap Depreciation
Depreciation
1110
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-2828954
us-gaap Net Income Loss
NetIncomeLoss
-62269946
us-gaap Net Income Loss
NetIncomeLoss
-6649481
us-gaap Share Based Compensation
ShareBasedCompensation
6214853
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33799503
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51050182
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34139672
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43053426
dei Entity Central Index Key
EntityCentralIndexKey
0001719406
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term Cancelled
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermCancelled
P0Y
dei Entity Registrant Name
EntityRegistrantName
NRX Pharmaceuticals, Inc.
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42973462
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
0
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.40
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.15
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-7.35
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.20
CY2021Q3 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term Exercised
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermExercised
P0Y
nrxp Number Of Shares Per Unit
NumberOfSharesPerUnit
1
nrxp Number Of Shares Per Right
NumberOfSharesPerRight
1
nrxp Demand Right Term
DemandRightTerm
P5Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39412
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2844431
dei Entity Address Address Line1
EntityAddressAddressLine1
1201 Orange Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmington
dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19801
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
254-6134
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58810338
CY2021Q3 us-gaap Cash
Cash
38883569
CY2020Q4 us-gaap Cash
Cash
1858513
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
257463
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
831390
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6350889
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
240352
CY2021Q3 us-gaap Assets Current
AssetsCurrent
45234458
CY2020Q4 us-gaap Assets Current
AssetsCurrent
2930255
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15921
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10914
CY2021Q3 us-gaap Assets
Assets
45250379
CY2020Q4 us-gaap Assets
Assets
2941169
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5559412
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3153310
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1995961
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1728483
CY2021Q3 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
1154042
CY2020Q4 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
1547432
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
26283238
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
775263
CY2021Q3 nrxp Notes Payable And Accrued Interest Current
NotesPayableAndAccruedInterestCurrent
515059
CY2020Q4 nrxp Notes Payable And Accrued Interest Current
NotesPayableAndAccruedInterestCurrent
248861
CY2020Q4 nrxp Accrued Settlement Expense
AccruedSettlementExpense
39486139
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
36282975
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46164225
CY2020Q4 nrxp Notes Payable And Accrued Interest Non Current
NotesPayableAndAccruedInterestNonCurrent
547827
CY2021Q3 us-gaap Liabilities
Liabilities
36282975
CY2020Q4 us-gaap Liabilities
Liabilities
46712052
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54810338
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42973462
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
54810
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
42974
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
161362260
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
46365863
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152449666
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90179720
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
8967404
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-43770883
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45250379
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2941169
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6275911
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4331709
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13843895
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6326416
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13823240
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3753704
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28382177
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4895092
nrxp Settlement Expense
SettlementExpense
21365641
CY2020Q3 nrxp Expense Reimbursement
ExpenseReimbursement
2936214
nrxp Expense Reimbursement
ExpenseReimbursement
771244
nrxp Expense Reimbursement
ExpenseReimbursement
4957145
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
20099151
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
5149199
us-gaap Operating Expenses
OperatingExpenses
62820469
us-gaap Operating Expenses
OperatingExpenses
6264363
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20099151
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5149199
us-gaap Operating Income Loss
OperatingIncomeLoss
-62820469
us-gaap Operating Income Loss
OperatingIncomeLoss
-6264363
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
120810
CY2021Q3 us-gaap Interest Expense
InterestExpense
5368
CY2020Q3 us-gaap Interest Expense
InterestExpense
12513
us-gaap Interest Expense
InterestExpense
15656
us-gaap Interest Expense
InterestExpense
51317
CY2021Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-260238
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1208412
CY2021Q3 nrxp Gain Loss On Fair Value Of Cash Earn Out Liability
GainLossOnFairValueOfCashEarnOutLiability
-408342
nrxp Gain Loss On Fair Value Of Cash Earn Out Liability
GainLossOnFairValueOfCashEarnOutLiability
-763043
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-27160
nrxp Gain Loss On Conversion Of Debt
GainLossOnConversionOfDebt
-306641
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-673948
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12513
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
550523
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-385118
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20773099
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5161712
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62269946
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6649481
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20773099
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-5161712
us-gaap Net Income Loss
NetIncomeLoss
-62269946
us-gaap Net Income Loss
NetIncomeLoss
-6649481
nrxp Deemed Dividend Warrants
DeemedDividendWarrants
2691799
nrxp Deemed Dividend Earnout Shares
DeemedDividendEarnoutShares
253130272
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20773099
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5161712
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-318092017
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6649481
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.40
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.15
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-7.35
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.20
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51739452
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34139672
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43290675
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33799503
CY2020Q4 nrxp Stockholders Equity As Previously Reported
StockholdersEquityAsPreviouslyReported
-43778472
CY2020Q4 nrxp Retroactive Application Of Reverse Recapitalization Value
RetroactiveApplicationOfReverseRecapitalizationValue
7589
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-43770883
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6927086
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7500018
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
60851779
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
371698
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-25488874
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
6390824
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1562272
CY2021Q2 nrxp Net Of Redemptions And Issuance Costs
NetOfRedemptionsAndIssuanceCosts
1412846
CY2021Q2 nrxp Stock Repurchased During Period Value Merger And Recapitalization Net Of Redemptions And Issuance Costs
StockRepurchasedDuringPeriodValueMergerAndRecapitalizationNetOfRedemptionsAndIssuanceCosts
26615796
CY2021Q2 nrxp Financing Net Of Issuance Costs
FinancingNetOfIssuanceCosts
1900000
CY2021Q2 nrxp Stock Issued During Period Value New Issues From Private Investment In Equity
StockIssuedDuringPeriodValueNewIssuesFromPrivateInvestmentInEquity
8100000
CY2021Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
4850000
CY2021Q2 nrxp Adjustments To Additional Paid In Capital Modifications Of Stock Options Due To Business Combination
AdjustmentsToAdditionalPaidInCapitalModificationsOfStockOptionsDueToBusinessCombination
1014640
CY2021Q2 nrxp Adjustments To Additional Paid In Capital Modifications Of Warrant Issued Due To Business Combination
AdjustmentsToAdditionalPaidInCapitalModificationsOfWarrantIssuedDueToBusinessCombination
2330572
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
938118
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16007973
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-17437343
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1134816
CY2021Q3 nrxp Sale Of Stock And Warrants Issuance Costs
SaleOfStockAndWarrantsIssuanceCosts
3668737
CY2021Q3 nrxp Common Stock And Warrants Issued In Private Placement Net Of Issuance Costs
CommonStockAndWarrantsIssuedInPrivatePlacementNetOfIssuanceCosts
-27358223
CY2021Q3 nrxp Issuance Of Stock For Exercise Of Warrants And Option
IssuanceOfStockForExerciseOfWarrantsAndOption
9199471
CY2021Q3 nrxp Stock Issued For Payment Of Consulting Services
StockIssuedForPaymentOfConsultingServices
7925511
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1559825
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20773099
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
8967404
CY2019Q4 nrxp Stockholders Equity As Previously Reported
StockholdersEquityAsPreviouslyReported
-4850950
CY2019Q4 nrxp Retroactive Application Of Reverse Recapitalization Value
RetroactiveApplicationOfReverseRecapitalizationValue
7545
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-4843405
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
177025
CY2020Q1 nrxp Convertible Preferred Stock Value Issued
ConvertiblePreferredStockValueIssued
50013
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
88803
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1590056
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-6117620
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
93466
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
102287
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-5921867
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1412067
CY2020Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3962126
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2689684
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
190749
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-5161712
us-gaap Share Based Compensation
ShareBasedCompensation
373018
nrxp Non Cash Warrant Issuance Expenses
NonCashWarrantIssuanceExpenses
2689684
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
120810
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
629523
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
50004
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9623899
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1589103
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16699489
nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
27358223
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
11049628
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-1100000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1208412
nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
-763043
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-27160
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
16475
us-gaap Paid In Kind Interest
PaidInKindInterest
15655
us-gaap Paid In Kind Interest
PaidInKindInterest
35198
nrxp Noncash Settlement Expense
NoncashSettlementExpense
21365641
nrxp Non Cash Consulting Expense
NonCashConsultingExpense
12775511
nrxp Gain Loss On Conversion Of Debt
GainLossOnConversionOfDebt
-306641
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-831390
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1254090
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6051045
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
460586
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1853855
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1330175
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-594437
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1726402
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26423097
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1858294
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
6612
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6612
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
-176474
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63454765
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2268630
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
37025056
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
410336
CY2020Q4 us-gaap Cash
Cash
1858513
CY2019Q4 us-gaap Cash
Cash
877421
CY2021Q3 us-gaap Cash
Cash
38883569
CY2020Q3 us-gaap Cash
Cash
1287757
nrxp Reclassification Of Settlement Liability Upon Issuance Of Warrant
ReclassificationOfSettlementLiabilityUponIssuanceOfWarrant
60851779
nrxp Extinguishment Of Paycheck Protection Program Loan
ExtinguishmentOfPaycheckProtectionProgramLoan
120810
nrxp Issuance Of Common Stock Warrants As Offering Costs
IssuanceOfCommonStockWarrantsAsOfferingCosts
1026957
nrxp Issuance Of Common Stock Warrants As Offering Costs
IssuanceOfCommonStockWarrantsAsOfferingCosts
30536
us-gaap Stock Issued1
StockIssued1
3655461
CY2021Q3 us-gaap Cash
Cash
38883569
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of common and preferred stock, stock options, warrants, contingent consideration and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk and Off-Balance Sheet Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash is the only financial instrument that is potentially subject to concentrations of credit risk. The Company’s cash is deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held. The Company has no financial instruments with off-balance sheet risk of loss.</p>
nrxp Deemed Dividend Earnout Shares
DeemedDividendEarnoutShares
253130272
nrxp Option Exchange Ratio Shares Earnout Shares For Common Stockholders
OptionExchangeRatioSharesEarnoutSharesForCommonStockholders
22209280
nrxp Option Exchange Ratio Value Earnout Cash For Common Stockholders
OptionExchangeRatioValueEarnoutCashForCommonStockholders
88837121
CY2020Q1 nrxp Accrued Interest
AccruedInterest
369660
CY2020Q1 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
132739
CY2020Q1 nrxp Discounted Stock Price Per Share
DiscountedStockPricePerShare
2.78
CY2020Q3 nrxp Common Stock Fair Value Outstanding
CommonStockFairValueOutstanding
0
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
3767488
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
49029
CY2021Q3 nrxp Prepaid Manufacturing Expenses Current
PrepaidManufacturingExpensesCurrent
1407500
CY2021Q3 nrxp Prepaid Clinical Development Expenses
PrepaidClinicalDevelopmentExpenses
720686
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
455215
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
164772
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
26551
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6350889
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
240352
CY2021Q3 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
625139
CY2020Q4 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
586426
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
530500
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
685802
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
606553
CY2021Q3 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
651835
CY2021Q3 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
33185
CY2020Q4 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
5004
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1995961
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1728483
CY2020Q1 us-gaap Common Unit Issuance Value
CommonUnitIssuanceValue
10000000
CY2020Q1 nrxp Fair Value Of Performance Shares Granted Per Share
FairValueOfPerformanceSharesGrantedPerShare
10.63
nrxp Common Stock Fair Value Outstanding
CommonStockFairValueOutstanding
306641
us-gaap Interest Paid
InterestPaid
0
CY2020Q3 us-gaap Interest Paid
InterestPaid
0
us-gaap Interest Paid
InterestPaid
0
CY2021Q3 us-gaap Interest Paid
InterestPaid
0
CY2020Q2 us-gaap Debt Instrument Term
DebtInstrumentTerm
P2Y
CY2020Q2 us-gaap Debt Instrument Description
DebtInstrumentDescription
The PPP Loan amount may be eligible for forgiveness in the event that (1) at least 75% of the PPP Loan proceeds are used to cover payroll costs and the remainder is used for mortgage interest, rent and utility costs over the eight week period after the PPP Loan is made, and (2) the number of employees and compensation levels are generally maintained.
nrxp Outstanding Principal Written Off
OutstandingPrincipalWrittenOff
119842
nrxp Outstanding Accrued And Unpaid Interest Written Off
OutstandingAccruedAndUnpaidInterestWrittenOff
968
CY2021Q3 nrxp Carrying Value Of Issued Notes
CarryingValueOfIssuedNotes
-500000
CY2020Q4 nrxp Carrying Value Of Issued Notes
CarryingValueOfIssuedNotes
-774032
CY2021Q3 nrxp Accrued Interest
AccruedInterest
15059
CY2020Q4 nrxp Accrued Interest
AccruedInterest
22656
nrxp Conversion Of Notes Payable And Accrued Interest
ConversionOfNotesPayableAndAccruedInterest
515059
CY2020 nrxp Conversion Of Notes Payable And Accrued Interest
ConversionOfNotesPayableAndAccruedInterest
796688
CY2021Q3 nrxp Notes Payable And Accrued Interest Current
NotesPayableAndAccruedInterestCurrent
515059
CY2020Q4 nrxp Notes Payable And Accrued Interest Current
NotesPayableAndAccruedInterestCurrent
248861
CY2020Q4 nrxp Notes Payable And Accrued Interest Non Current
NotesPayableAndAccruedInterestNonCurrent
547827
CY2021Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
9162
CY2020Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
14174
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
64555
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
32076
CY2020Q3 nrxp Percentage Of Annual Product Requirement
PercentageOfAnnualProductRequirement
1
CY2021Q1 nrxp Settlement Expense
SettlementExpense
21365641
CY2021Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1833596
CY2021Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9186316
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
511065
CY2021Q3 nrxp Contingent Earnout Shares Excluded From Eps Computation
ContingentEarnoutSharesExcludedFromEpsComputation
185472
CY2021Q3 nrxp Issuance Of Stock For Exercise Of Warrants And Option
IssuanceOfStockForExerciseOfWarrantsAndOption
9199471
nrxp Issuance Of Stock For Exercise Of Warrants And Option
IssuanceOfStockForExerciseOfWarrantsAndOption
16699489
CY2021Q3 nrxp Shares Of Stock Issued For Payment Of Consulting Services
SharesOfStockIssuedForPaymentOfConsultingServices
634045
nrxp Shares Of Stock Issued For Payment Of Consulting Services
SharesOfStockIssuedForPaymentOfConsultingServices
834045
CY2021Q3 nrxp Non Cash Consulting Expense
NonCashConsultingExpense
7925511
nrxp Non Cash Consulting Expense
NonCashConsultingExpense
12775511
us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
1138199
nrxp Gain Loss On Conversion Of Debt
GainLossOnConversionOfDebt
-306641
CY2021Q3 nrxp Class Of Warrant Or Right Granted Intrinsic Value
ClassOfWarrantOrRightGrantedIntrinsicValue
4858637
CY2021Q3 nrxp Warrants Exercised During Period
WarrantsExercisedDuringPeriod
1834740
CY2021Q3 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Assumed Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAssumedExercised
3.19
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.63
CY2021Q2 nrxp Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
42385824
CY2021Q3 nrxp Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
2863637
CY2021Q3 nrxp Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
P3Y
CY2021Q3 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
12.08
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3075470
CY2020 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P4Y4M2D
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.09
CY2020Q4 nrxp Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
150955963
CY2021Q1 nrxp Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
3329812
CY2021Q1 nrxp Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
P3Y
CY2021Q1 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
3.19
CY2021Q1 nrxp Class Of Warrant Or Right Granted Intrinsic Value
ClassOfWarrantOrRightGrantedIntrinsicValue
111082528
CY2021Q1 nrxp Warrants Exercised During Period
WarrantsExercisedDuringPeriod
1496216
CY2021Q1 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Assumed Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAssumedExercised
3.19
CY2021Q1 nrxp Warrants Exercised Aggregate Intrinsic Value
WarrantsExercisedAggregateIntrinsicValue
49913766
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4909066
CY2021Q1 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P3Y8M26D
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.78
CY2021Q1 nrxp Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
244574345
CY2021Q2 nrxp Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
3586250
CY2021Q2 nrxp Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
P5Y
CY2021Q2 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
11.50
CY2021Q2 nrxp Class Of Warrant Or Right Granted Intrinsic Value
ClassOfWarrantOrRightGrantedIntrinsicValue
45724688
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8495316
CY2021Q2 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P4Y1M2D
CY2021Q3 nrxp Warrants Exercised Aggregate Intrinsic Value
WarrantsExercisedAggregateIntrinsicValue
17498538
CY2021Q3 nrxp Class Of Warrant Or Right Forfeited
ClassOfWarrantOrRightForfeited
218423
CY2021Q3 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Cancelled
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelled
1.53
CY2021Q3 nrxp Warrants Canceled Or Forfeited Aggregate Intrinsic Value
WarrantsCanceledOrForfeitedAggregateIntrinsicValue
1500566
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9305790
CY2021Q3 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P3Y10M13D
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.09
CY2021Q3 nrxp Class Of Warrant Or Right Outstanding Intrinsic Value
ClassOfWarrantOrRightOutstandingIntrinsicValue
17770340
CY2021Q3 nrxp Number Of Units Outstanding
NumberOfUnitsOutstanding
600000
CY2021Q3 nrxp Unit Price
UnitPrice
10.00
CY2021Q3 nrxp Aggregate Exercise Price
AggregateExercisePrice
6000000
nrxp Unit Expiration Term
UnitExpirationTerm
P5Y
nrxp Piggy Back Right Term
PiggyBackRightTerm
P7Y
CY2021Q3 nrxp Number Of Units Outstanding
NumberOfUnitsOutstanding
600000
CY2021Q3 nrxp Number Of Shares Of Common Stock Created In Conversion
NumberOfSharesOfCommonStockCreatedInConversion
499630
nrxp Number Of Shares Per Right
NumberOfSharesPerRight
1
nrxp Fractional Shares Issued Upon Conversion Of Rights
FractionalSharesIssuedUponConversionOfRights
0
nrxp Embedded Derivative Liability Expected Dividend Yield
EmbeddedDerivativeLiabilityExpectedDividendYield
0
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
32644383
CY2021Q1 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueForfeited
6587328
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2919493
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.25
CY2021Q2 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
20558299
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.53
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.62
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.44
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0069
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0124
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0079
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.800
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2414303
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.17
CY2020 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
53659966
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
210800
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.69
CY2021Q1 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted
P9Y9M18D
CY2021Q1 nrxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted
3825276
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
198400
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.22
CY2021Q3 nrxp Allocated Share Based Compensation Expense Expected To Be Recognized In Future
AllocatedShareBasedCompensationExpenseExpectedToBeRecognizedInFuture
8152105
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M23D
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1559825
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
190750
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6214853
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
373018
CY2021Q3 us-gaap Share Price
SharePrice
9.27
CY2020Q4 us-gaap Share Price
SharePrice
11.62
CY2021Q3 nrxp Strike Price
StrikePrice
11.50
CY2020Q4 nrxp Strike Price
StrikePrice
11.50
nrxp Warrant Liability Fair Value Assumptions Expected Term
WarrantLiabilityFairValueAssumptionsExpectedTerm
P4Y7M24D
CY2020 nrxp Warrant Liability Fair Value Assumptions Expected Term
WarrantLiabilityFairValueAssumptionsExpectedTerm
P4Y10M24D
nrxp Warrant Liability Fair Value Assumptions Expected Volatility Rate
WarrantLiabilityFairValueAssumptionsExpectedVolatilityRate
0.859
CY2020 nrxp Warrant Liability Fair Value Assumptions Expected Volatility Rate
WarrantLiabilityFairValueAssumptionsExpectedVolatilityRate
0.357
nrxp Warrant Liability Fair Value Assumptions Risk Free Interest Rate
WarrantLiabilityFairValueAssumptionsRiskFreeInterestRate
0.009
CY2020 nrxp Warrant Liability Fair Value Assumptions Risk Free Interest Rate
WarrantLiabilityFairValueAssumptionsRiskFreeInterestRate
0.0085
CY2021Q3 nrxp Fair Value Of Warrants
FairValueOfWarrants
5.69
CY2020Q4 nrxp Fair Value Of Warrants
FairValueOfWarrants
3.78
nrxp Estimated Trading Price
EstimatedTradingPrice
24.25
nrxp Deemed Dividend Earnout Shares
DeemedDividendEarnoutShares
253130272
nrxp Net Impact To Additional Paid In Capital
NetImpactToAdditionalPaidInCapital
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
138501
CY2020Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
149067

Files In Submission

Name View Source Status
0001558370-21-015962-index-headers.html Edgar Link pending
0001558370-21-015962-index.html Edgar Link pending
0001558370-21-015962.txt Edgar Link pending
0001558370-21-015962-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrxp-20210930.xsd Edgar Link pending
nrxp-20210930x10q.htm Edgar Link pending
nrxp-20210930x10q_htm.xml Edgar Link completed
nrxp-20210930xex10d1.htm Edgar Link pending
nrxp-20210930xex10d1001.jpg Edgar Link pending
nrxp-20210930xex31d1.htm Edgar Link pending
nrxp-20210930xex31d2.htm Edgar Link pending
nrxp-20210930xex32d1.htm Edgar Link pending
nrxp-20210930xex32d2.htm Edgar Link pending
nrxp-20210930_cal.xml Edgar Link unprocessable
nrxp-20210930_def.xml Edgar Link unprocessable
nrxp-20210930_lab.xml Edgar Link unprocessable
nrxp-20210930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending